{"retracted":false,"update":{"timestamp":1158019200000,"doi":"10.1212/01.wnl.0000244478.20128.b8","type":"correction"},"doi":"10.1212/01.wnl.0000204235.81272.e2","journal":"Neurology","publisher":"Ovid Technologies (Wolters Kluwer Health)","title":"Randomized controlled phase II trial of glatiramer acetate in ALS"}
